Medical devices, healthcare technology and the business of care
PMA approval · P250010

ProlivRx System

Neurolief , Ltd. · Decision date Dec 31, 2025

FDA DECISIONP250010

What did the FDA approve?

FDA records P250010 as an original PMA application. The recorded decision is approval, dated Dec 31, 2025.

FDA approval order statement

The ProlivRx System provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment. It is intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in clinic. It is a prescription-only device.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Dec 31, 2025

FDA source record

Regulatory record facts

Identifier
P250010
Regulatory pathway
Premarket approval application
Product code
JXK
Decision code
APPR
Decision date
Dec 31, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cranial electrotherapy stimulator to treat depression.

Product code
JXK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250010 received

    Application receipt date recorded by FDA.

  2. P250010 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250010. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code JXK

Product / regulatory recordCompanyPathwayDecision dateSource
Flow FL-100P230024/S001
Flow Neuroscience ABPMA supplementJul 14, 2026FDA
Flow Neuroscience ABPMA approvalDec 8, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Neurolief , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
12 Giborei Israel St., Netanya, 4250412

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records